{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:44:56Z","timestamp":1777452296423,"version":"3.51.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,30]],"date-time":"2015-07-30T00:00:00Z","timestamp":1438214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.msard.2015.07.017","type":"journal-article","created":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T03:40:51Z","timestamp":1438400451000},"page":"536-545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Placebo controlled trials in neuromyelitis optica are needed and ethical"],"prefix":"10.1016","volume":"4","author":[{"given":"Bruce A.C.","family":"Cree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2015.07.017_bib1","doi-asserted-by":"crossref","unstructured":"\u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050722s021,050723s019,050758s019,050759s024lbl.pdf\u3009, accessed February 23, 2014c.","DOI":"10.1007\/s00415-009-5171-x"},{"key":"10.1016\/j.msard.2015.07.017_bib2","doi-asserted-by":"crossref","unstructured":"\u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103705s5311lbl.pdf\u3009, accessed February 23, 2014d.","DOI":"10.1007\/s00415-013-6926-y"},{"key":"10.1016\/j.msard.2015.07.017_bib3","unstructured":"\u3008http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/016324s034s035lbl.pdf\u3009, accessed February 23, 2014b."},{"key":"10.1016\/j.msard.2015.07.017_bib4","unstructured":"\u3008http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/\u3009, accessed February 23, 2014a."},{"key":"10.1016\/j.msard.2015.07.017_bib5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/j.msard.2015.07.017_bib6","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","article-title":"Population-based study of neuromyelitis optica in Caucasians","volume":"76","author":"Asgari","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2015.07.017_bib8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10875-012-9808-7","article-title":"Comment on neuromyelitis optica: potential roles for intravenous immunoglobulin","volume":"33","author":"Bichuetti","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2015.07.017_bib9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneurol.2012.545","article-title":"Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients","volume":"69","author":"Bichuetti","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2015.07.017_bib11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/NRL.0b013e31820a9d35","article-title":"A review of cases of neuromyelitis optica","volume":"17","author":"Bomprezzi","year":"2011","journal-title":"Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Under the Aegis of the French National Observatory of Multiple Sclerosis: efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2015.07.017_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Transforms study group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"9856","key":"10.1016\/j.msard.2015.07.017_bib15","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2015.07.017_bib16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib17","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2015.07.017_bib18","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial","volume":"324","author":"Echt","year":"1991","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2015.07.017_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult. Scler."},{"issue":"10","key":"10.1016\/j.msard.2015.07.017_bib20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe Parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.msard.2015.07.017_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM198707163170304","article-title":"Equipoise and the ethics of clinical research","volume":"317","author":"Freedman","year":"1987","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2015.07.017_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"Placebo-controlled trials and the logic of clinical purpose","volume":"12","author":"Freedman","year":"1990","journal-title":"IRB"},{"key":"10.1016\/j.msard.2015.07.017_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0002-9343(98)00372-6","article-title":"Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial","volume":"106","author":"Galindo-Rodriguez","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.msard.2015.07.017_bib24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2013.02.024","article-title":"Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases","volume":"328","author":"Gredler","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2015.07.017_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/01.wnl.0000342200.58823.6a","article-title":"Levels of evidence: taking neurology to the next level","volume":"72","author":"Gross","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib26","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2015.07.017_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women heart and estrogen\/progestin replacement study (HERS) research group","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2015.07.017_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2012.09.024","article-title":"Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders","volume":"324","author":"Ip","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2015.07.017_bib29","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib30","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2015.07.017_bib31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s00415-013-6926-y","article-title":"The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom","volume":"260","author":"Jacob","year":"2013","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2015.07.017_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","article-title":"AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance","volume":"6","author":"Jarius","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib33","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.msard.2015.07.017_bib34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","article-title":"Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica","volume":"260","author":"Kageyama","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib36","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2015.07.017_bib37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.23863","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2015.07.017_bib38","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2015.07.017_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"For the neuromyelitis optica study group: failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2015.07.017_bib40","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e318218107a","article-title":"Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis","volume":"76","author":"Krupp","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2015.07.017_bib42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"CombiRx Investigators. Randomized study combining interferon and glatiramer acetate in multiple sclerosis","volume":"73","author":"Lublin","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia"},{"key":"10.1016\/j.msard.2015.07.017_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.msard.2015.07.017_bib47","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7224\/1537-2073-2.4.43","article-title":"Treatment of Devic\u2019s disease with methotrexate and prednisone","volume":"2","author":"Minegar","year":"2000","journal-title":"Int. J. MS Care"},{"issue":"1","key":"10.1016\/j.msard.2015.07.017_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.44.1.16","article-title":"The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial","volume":"44","author":"Noseworthy","year":"1994","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2015.07.017_bib50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250microg or 500microg interferon beta-1b vs. 20mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor","year":"2009","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2015.07.017_bib51","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2015.07.017_bib52","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib53","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2015.07.017_bib54","first-page":"14","article-title":"Treatment of neuromyelitis optica\/neuromyelitis optica spectrum disorders with methotrexate","volume":"15","author":"Ramanathan","year":"2014","journal-title":"BMC Neurol."},{"issue":"3","key":"10.1016\/j.msard.2015.07.017_bib55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2015.07.017_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.msard.2015.07.017_bib57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"New Engl. J. Med."},{"issue":"7023","key":"10.1016\/j.msard.2015.07.017_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: what it is and what it isn't","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2015.07.017_bib59","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1468-1331.2009.02928.x","article-title":"Relapsing neuromyelitis optics: demographic and clinical features in Iranian patients","volume":"17","author":"Sahraian","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2015.07.017_bib60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2015.07.017_bib61","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"16","key":"10.1016\/j.msard.2015.07.017_bib62","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2015.07.017_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","article-title":"Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence","volume":"20","author":"Stampfer","year":"1991","journal-title":"Prev. Med."},{"issue":"32","key":"10.1016\/j.msard.2015.07.017_bib64","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2009.24.6678","volume":"27","author":"Strauss","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9065","key":"10.1016\/j.msard.2015.07.017_bib65","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","article-title":"A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group","volume":"349","author":"The International Stroke Trial","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2015.07.017_bib66","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jama.1995.03520320035038","article-title":"Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful: results of the Ischemic Optic Neuropathy Decompression Trial (IONDT)","volume":"273","author":"The Ischemic Optic Neuropathy Decompression Trial Research Group","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.msard.2015.07.017_bib67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2015.07.017_bib68","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic's disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2015.07.017_bib69","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2015.07.017_bib70","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","article-title":"Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder","volume":"52","author":"Yaguchi","year":"2013","journal-title":"Intern. Med."},{"key":"10.1016\/j.msard.2015.07.017_bib71","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034815001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034815001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:02:43Z","timestamp":1567036963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034815001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S2211034815001169"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2015.07.017","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo controlled trials in neuromyelitis optica are needed and ethical","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2015.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}